Treatment of Hodgkin's Lymphoma in Nodular Lymphocyte-Predominant B-Cell Lymphoma (NLPBL) with CD20-Expressing Cells
This protocol is specific to patients with nodular lymphocyte-predominant B-cell lymphoma (NLPBL) — a subtype of Hodgkin's lymphoma in which the lymphoma cells characteristically express CD20. This biological distinction directly shapes treatment selection.
Why NLPBL Requires a Different Approach
NLPBL tends to progress more slowly than classical Hodgkin's lymphoma. Because of this difference in behaviour and biology, the standard classical HL treatment pathway does not apply directly to NLPBL patients. A distinct clinical approach is needed, informed by both the disease's natural history and the CD20 expression on lymphoma cells.
Regimen Direction (Partial)
When treatment is required, combination chemotherapy may be considered — and because NLPBL lymphoma cells express CD20, rituximab may be incorporated into the regimen to target those cells directly. The complete set of options and the full clinical pathway are available in the structured protocol.
References
NLPBL tends to progress more slowly than classical HL, so the treatment approach is usually different.
The treatment for nodular lymphocyte-predominant B-cell lymphoma (formerly called nodular lymphocyte-predominant Hodgkin lymphoma) requires a different treatment approach.
Combination chemotherapy may be needed in more advanced stages of the disease, with rituximab (Rituxan®) added to the regimen in some cases.
Common treatments used in advanced NLPBL include: R + ABVD—rituximab plus doxorubicin, bleomycin, vinblastine, dacarbazine; R + B—rituximab plus bendamustine; R-CHOP—rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone; R-CVP—rituximab plus cyclophosphamide, vinblastine, prednisone; Rituximab alone.
View source ↗